J. W. Butcher

发表

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

E. A. O'neill, J. Vacca, B. Frantz, 1999, Journal of Medicinal Chemistry.

Synthesis of the first sulfur-35-labeled hERG radioligand.

N. Liverton, C. Raab, D. Dean, 2006, Bioorganic & medicinal chemistry letters.

Preparation of 3-amino-1,4-benzodiazepin-2-ones via direct azidation with trisyl azide

N. Liverton, A. Tebben, H. Selnick, 1996 .

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

E. A. O'neill, J. Vacca, B. Frantz, 1999, Journal of medicinal chemistry.

Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.

M. Rudd, P. Coleman, S. Harper, 2012, ACS medicinal chemistry letters.

Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.

M. Rudd, D. Graham, M. Holloway, 2010, Journal of medicinal chemistry.

Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.

M. Rudd, D. Graham, M. Holloway, 2011, ACS medicinal chemistry letters.

Synthesis of the first sulfur-35-labeled hERG radioligand.

N. Liverton, C. Raab, D. Dean, 2006, Bioorganic & medicinal chemistry letters.

Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide.

J J Baldwin, M. Sanguinetti, R. Freidinger, 1997, Journal of medicinal chemistry.

Synthesis of semisynthetic dipeptides using N-carboxyanhydrides and chiral induction on raney nickel. A method practical for large scale

J. W. Butcher, Thomas J. Blacklock, R. Shuman, 1988 .

Inhibition of human leukocyte elastase. 1. Inhibition by C-7-substituted cephalosporin tert-butyl esters.

J. W. Butcher, J. Doherty, P. Barker, 1990, Journal of medicinal chemistry.

A versatile synthesis of 1,1-dioxo 7-substituted cephems: preparation of the human leukocyte elastase (HLE) inhibitor 1,1-dioxo-trans-7-methoxycephalosporanic acid tert-butyl ester

E. Grabowski, J. W. Butcher, T. Blacklock, 1989 .

Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.

Qian Huang, Adam T. Gates, M. Rudd, 2012, Bioorganic & medicinal chemistry letters.

P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325

Qian Huang, Adam T. Gates, M. Rudd, 2015, ChemMedChem.

Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.

M. Katharine Holloway, M. Rudd, M. Holloway, 2008, Journal of the American Chemical Society.

Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.

A. Dilella, N. Liverton, C. Claiborne, 2007, Journal of medicinal chemistry.

An enantioselective synthesis of the topically-active carbonic anhydrase inhibitor MK-0507: 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide hydrochloride

E. Grabowski, J. W. Butcher, T. Blacklock, 1993 .

Preparation and trapping of 3-lithium-O-lithiophenoxide

H. Selnick, M. Bourgeois, J. W. Butcher, 1993 .

4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121).

B. T. Phillips, J. Baldwin, C. N. Habecker, 1992, Journal of medicinal chemistry.

Novel 5-cyclopropyl-1,4-benzodiazepin-2-ones as potent and selective I(Ks)-blocking class III antiarrhythmic agents.

R. Freidinger, N. Liverton, C. Dieckhaus, 2003, Bioorganic & medicinal chemistry letters.

Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

Matthew L. Maddess, H. Houshyar, M. Altman, 2015, Journal of medicinal chemistry.

A new series of potent benzodiazepine γ-secretase inhibitors

I. Churcher, J. W. Butcher, H. Lewis, 2003 .

A new series of potent benzodiazepine gamma-secretase inhibitors.

I. Churcher, J. W. Butcher, H. Lewis, 2003, Bioorganic & Medicinal Chemistry Letters.

Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.

M. Rudd, D. Graham, J. Vacca, 2010, Journal of medicinal chemistry.

Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.

M. Rudd, D. Graham, J. Vacca, 2011, ACS medicinal chemistry letters.

Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.

R. Freidinger, N. Liverton, J. Mccauley, 2009, Bioorganic & medicinal chemistry letters.